Please assess the completion status of the following clinical trial:

Trial Title: Allergy Immunotherapy for the Reduction of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 18 months through 3 years who had at least 2 episodes of wheezing prior to enrolment.~* Positive skin tests or specific Immunoglobulin E (IgE) antibody titers to at least one of common airborne allergens: Dust Mite, cat, cockroach, mouse, dog, pollen (all allergy testing can be done at the screening visit at the study site).~* The child must also fulfill the criteria for high risk of developing persistent asthma by meeting at least one of the following major conditions OR 2 of the following minor conditions:~  * Major criteria: History of atopic dermatitis and/or parental history of asthma.~ * Minor criteria: MD-diagnosed allergic rhinitis, wheezing unrelated to colds, blood eosinophils above 4%.~Exclusion Criteria:~* The child has a severe systemic condition (other than allergy or asthma) including (but not limited to) seizures, major congenital anomalies, physical and intellectual delay, cerebral palsy, chest surgery, tuberculosis, primary or secondary immunodeficiency or cardiac disorder (except a hemodynamically insignificant atrial or ventricular septum defect or heart murmur).~* The child was born following 35 or less weeks of gestation.~* Parental report that the child received oxygen for more than 5 days in the neonatal period, or required mechanical ventilation at any time since birth.~* The child fails to thrive, defined as crossing of two major growth percentile lines during the last year.~* The child has chronic lung disease of prematurity (CLDP), cystic fibrosis or any other chronic lung disease.~* The child ever received immunotherapy.~* The child ever received i.v. gammaglobulins or immunosuppressants (other than corticosteroids for asthma).~* History of a life-threatening asthma exacerbation which required intubation and mechanical ventilation.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- No immunotherapy, receive standard of care asthma treatment (Type: ACTIVE_COMPARATOR): This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
- Allergen immunotherapy (Type: EXPERIMENTAL): This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).